Huapont Pharmaceutical Co
Huapont Pharmaceutical Co., Ltd., commonly referred to as Huapont, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1993, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong operational presence across various regions, Huapont is dedicated to advancing healthcare through innovative solutions. The company is recognised for its commitment to quality and compliance, which has positioned it favourably in both domestic and international markets. Notable achievements include a robust portfolio of core products that cater to various therapeutic areas, setting Huapont apart as a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Huapont Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huapont Pharmaceutical Co's score of 0 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Huapont Pharmaceutical Co's reported carbon emissions
Huapont Pharmaceutical Co, headquartered in China (CN), currently does not have publicly available data regarding its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined by the company. In the absence of concrete emissions data, it is essential to note that many pharmaceutical companies are increasingly focusing on sustainability and climate commitments. This includes efforts to reduce greenhouse gas emissions across various scopes, including Scope 1 (direct emissions), Scope 2 (indirect emissions from energy), and Scope 3 (indirect emissions from the supply chain). As the industry evolves, Huapont Pharmaceutical Co may consider establishing measurable targets and initiatives to align with global climate goals, reflecting a growing trend among pharmaceutical firms to enhance their environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Huapont Pharmaceutical Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
